A phase II evaluation of adriamycin and cis-platinum in hormone resistant prostate cancer
โ Scribed by Dennis L. Citrin; Tom F. Hogan
- Publisher
- John Wiley and Sons
- Year
- 1982
- Tongue
- English
- Weight
- 503 KB
- Volume
- 50
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
## Abstract Estrogen receptor (ER)โpositive acquired tamoxifenโresistant (TAMโR) MCFโ7 breast cancer cell lines exhibit epidermal growth factor receptor (EGFR) expression/signaling and are growthโinhibited by gefitinib (IRESSA). We examined the effect of gefitinib on ERโpositive TAMโR and ERโnegati
## BACKGROUND. A phase II trial, involving infusions of autologous dendritic cells (DC) and two human histocompatibility antigen (HLA-A2)-specific prostate-specific membrane antigen (PSMA) peptides, was recently completed. Thirty percent of the participants, including subjects with hormone-refract
## Background: In order to develop a hormone-resistant analog to the hormone sensitive cell-line lncap, different methods were tried. ## Methods: After almost one year of continuous culture in rpmi-1640, containing a low concentration of androgens, the hormone sensitive cell-line lncap became hor
To determine the efficacy of recombinant human leukocyte alpha-interferon (IFL-RA) in advanced hormone-refractory prostate cancer, the authors treated 40 patients with IFL-RA administered intramuscularly at a dose of 10 x 10' U/m2 three times weekly. Toxicity was substantial and necessitated at leas